Evaluating the Early Bactericidal Activity, Safety and Tolerability of Nebulised RESP301 in Adults With Tuberculosis
Status:
Recruiting
Trial end date:
2025-07-31
Target enrollment:
Participant gender:
Summary
A Phase 2, Single-Centre, Open-Label, Parallel Control Arm, Randomised Clinical Study to
Evaluate the Early Bactericidal Activity (EBA), Safety and Tolerability of Nebulised RESP301
in Adults with Newly Diagnosed, Rifampicin Susceptible Pulmonary Tuberculosis